Pfizer will halt its development of a weight-loss drug that was being closely watched by investors, in a significant blow to the US pharmaceutical group.
The company said on Monday that it would stop the development of the treatment, known as danuglipron, after a patient in one of its studies “experienced potential drug-induced liver injury”.
The New York based-drugmaker had hoped the daily pill would allow it to break into the booming obesity treatment market, after sales of its vaccine and other coronavirus-related products fell following the pandemic.
您已阅读18%（558字），剩余82%（2513字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。